Our Lamb Law Office Newsletter helps keep you up-to-date with some of the cases we are currently working on for our clients. Additionally, we offer an informational resource item that you or someone you know may find helpful.
Recent Newsletter Editions
For your convenience, below is a summary and link for the most recent editions of the Lamb Law Office Newsletter.
June 2025 — In this newsletter, we present information concerning a possible eye-related side effect, non-arteritic anterior ischemic optic neuropathy, also known as NAION, associated with tirzepatide-containing drugs Mounjaro and Zepbound being investigated by the FDA. If you have developed NAION with Mounjaro or Zepbound, there might be a drug injury lawsuit against the responsible pharmaceutical company. In this newsletter, we also point out an NIH MedlinePlus Magazine article, “7 tips for managing screen use”, intended to help families find a healthy balance with digital devices.
October 2024 — In this newsletter, we present information concerning brain tumors from birth control Depo-Provera injections that have resulted in some drug injury lawsuits being filed against the responsible pharmaceutical companies. Intracranial meningiomas are mostly non-cancerous or non-malignant tumors. However, there are also cancerous or malignant meningiomas. Both of these forms of intracranial meningioma are potentially serious medical conditions. We note that the lawsuit would not be against the woman’s doctors. In this newsletter, we also point out an NIH MedlinePlus Magazine article, “Glaucoma: What you need to know”.
July 2024 — In this newsletter, we present a recent medical study that shows Ozempic side effects include eye problems that can lead to vision loss. More specifically, nonarteritic anterior ischemic optic neuropathy (NAION) has been linked to semaglutide, the active ingredient in Ozempic, as well as Wegovy and Rybelsus. As such, this finding about the new NAION Ozempic eye side effect also applies to Wegovy and Rybelsus. Patients who developed NAION following the use of Ozempic, Wegovy, or Rybelsus may be entitled to legal compensation by filing a drug injury lawsuit against Novo Nordisk, the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus. In this newsletter, we also point you to an NIH MedlinePlus Magazine article about the importance of drinking enough water.
Lamb Law Office Newsletter Sign-up Form
You can sign up to receive our monthly newsletter by completing this form.